S&P Futures
2,432.50
+3.00 (+0.12%)Dow Futures
21,747.00
+14.00 (+0.06%)
| Previous Close | 147.40 |
| Open | 146.73 |
| Bid | 95.82 x 100 |
| Ask | 141.00 x 200 |
| Day's Range | 145.85 - 148.35 |
| 52 Week Range | 95.80 - 163.75 |
| Volume | 285,344 |
| Avg. Volume | 457,634 |
| Market Cap | 8.77B |
| Beta | 1.45 |
| PE Ratio (TTM) | 22.06 |
| EPS (TTM) | 6.62 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 184.63 |
- PR Newswire•16 hours ago
Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024
DUBLIN, Aug. 17, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), of $500 million aggregate principal amount of exchangeable senior notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer has also granted the initial purchasers a 13-day option to purchase up to an additional $75 million aggregate principal amount of notes. Jazz Pharmaceuticals plc intends to use the net proceeds from this offering to repay all or a substantial portion of $500 million of outstanding borrowings under its revolving credit facility. Any remaining net proceeds will be used for general corporate purposes, including potential business development activities.
- ACCESSWIRE•3 days ago
Earnings Review and Free Research Report: Illumina Reported Better Than Expected Revenue and Earnings Results
Research Desk Line-up: Jazz Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 15, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Illumina, Inc. (NASDAQ: ILMN ), ...
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of JAZZ earnings conference call or presentation 8-Aug-17 8:30pm GMT
Q2 2017 Jazz Pharmaceuticals PLC Earnings Call
